The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 5, 2014, Pages 555-560

  Hopkins, A M ^a   O'Doherty, C E ^a   Foster, D J R ^a   Suppiah, V ^a   Upton, R N ^a   Spargo, L D ^b   Cleland, L G ^b   Proudman, S M ^b,c   Wiese, M D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

leflunomide; pharmacogenomics; polymorphism; PTPN22; rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; SALAZOSULFAPYRIDINE; IMMUNOLOGICAL ADJUVANT; ISOXAZOLE DERIVATIVE; PTPN22 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; BLADDER DYSFUNCTION; CAUCASIAN; CONTROLLED STUDY; DAS28; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAIR LOSS; HAPLOTYPE; HEADACHE; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PULSATING TEETH; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TOOTH DISEASE; URINARY FREQUENCY; VOMITING; ARTHRITIS, RHEUMATOID; AUSTRALIA; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; SOUTH AUSTRALIA; TREATMENT OUTCOME;

EID: 84906939025     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12189     Document Type: Article

References (38)

1. Snir O, Widhe M, Hermansson M, et al,. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum, 2010; 62: 44-52.
2. Taylor P, Gartemann J, Hsieh J, Creeden J,. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis, 2011; 2011: 815038.
3. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E,. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1* 0401 MHC class II molecule. J Immunol, 2003; 171: 538-541.
4. Bowes J, Barton A,. Recent advances in the genetics of RA susceptibility. Rheumatology, 2008; 47: 399-402.
5. Scott DL, Wolfe F, Huizinga TWJ,. Rheumatoid arthritis. Lancet, 2010; 376: 1094-1108.
6. O'dell JR, Nepom BS, Haire C, et al,. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis, 1998; 57: 209-213.
7. Hider SL, Silman AJ, Thomson W, Lunt M, Bunn D, Symmons DP,. Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? Ann Rheum Dis, 2009; 68: 57-62.
8. Zhong M-C, Veillette A,. Immunology: Csk keeps LYP on a leash. Nat Chem Biol, 2012; 8: 412-413.
9. Hinks A, Eyre S, Barton A, Thomson W, Worthington J,. Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Ann Rheum Dis, 2007; 66: 683-686.
10. Begovich AB, Carlton VEH, Honigberg LA, et al,. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet, 2004; 75: 330-337.
11. Majorczyk E, Pawlik A, Kuśnierczyk P,. PTPN22 1858C> T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy. Int Immunopharmacol, 2010; 10: 1626-1629.
12. Gregersen PK, Behrens TW,. Genetics of autoimmune diseases-disorders of immune homeostasis. Nat Rev Genet, 2006; 7: 917-928.
13. Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, Chong AS,. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol, 1997; 159: 167-174.
14. Breedveld F, Dayer J,. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Br Med J, 2000; 59: 841.
15. Xu X, Williams JW, Bremer EG, Finnegan A, Chong ASF,. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem, 1995; 270: 12398-12403.
16. Smolen JS, Landewé R, Breedveld FC, et al,. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis, 2010; 69: 964-975.
17. Singh JA, Furst DE, Bharat A, et al,. 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res, 2012; 64: 625-639.
18. Kremer J, Genovese M, Cannon G, et al,. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med, 2002; 137: 726.
19. Dougados M, Emery P, Lemmel E, Zerbini C, Brin S, Van Riel P,. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis, 2005; 64: 44-51.
20. Alcorn N, Saunders S, Madhok R,. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf, 2009; 32: 1123-1134.
21. Arnett F, Edworthy S, Bloch D, et al,. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 2005; 31: 315-324.
22. Proudman SM, Keen HI, Stamp LK, et al,. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum, 2007; 37: 99-111.
23. Holoshitz J,. The rheumatoid arthritis HLA-DRB1 shared epitope. Curr Opin Rheumatol, 2010; 22: 293-298.
24. Smolen J, Aletaha D, Koeller M, Weisman M, Emery P,. New therapies for treatment of rheumatoid arthritis. Lancet, 2007; 370: 1861-1874.
25. O'doherty C, Schnabl M, Spargo L, Cleland LG, James M, Proudman SM, Wiese MD,. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics, 2012; 13: 1427-1434.
26. Wiese M, Schnabl M, O'doherty C, Spargo L, Sorich M, Cleland L, Proudman SM,. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res Ther, 2012; 14: R163.
27. Naranjo CA, Busto U, Sellers EM, et al,. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30: 239-245.
28. Van Roon EN, Jansen TLTA, Van De Laar MAFJ, et al,. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis, 2005; 64: 569-574.
29. Rakhila H, Rozek T, Hopkins A, et al,. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC -MS/MS. J Pharm Biomed Anal, 2011; 55: 325-331.
30. Potter C, Hyrich KL, Tracey A, et al,. Association of RF and anti-CCP positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-TNF response in RA. Ann Rheum Dis, 2008; 68: 69-74.
31. Maine CJ, Hamilton-Williams EE, Cheung J, et al,. PTPN22 alters the development of regulatory T cells in the thymus. J Immunol, 2012; 188: 5267-5275.
32. González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, Aragõn-Bodi A, Sánchez BD, Sánchez-Madrid F,. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis, 2009; 68: 1644-1650.
33. Oh S, Aitken M, Simons DM, et al,. Requirement for diverse TCR specificities determines regulatory T cell activity in a mouse model of autoimmune arthritis. J Immunol, 2012; 188: 4171-4180.
34. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE,. TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells. Blood, 2006; 108: 253-261.
35. Wesoly J, Van Der Helm Van Mil A, Toes R, et al,. Association of the PTPN22 C1858T single nucleotide polymorphism with rheumatoid arthritis phenotypes in an inception cohort. Arthritis Rheum, 2005; 52: 2948-2950.
36. Van Gestel AM, Haagsma CJ, Van Riel PL,. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum, 1998; 41: 1845-1850.
37. Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M,. The effect of exon (19C> A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics, 2009; 10: 303-309.
38. Grabar B, Rozman B, Tomši M, Šuput D, Logar D, Dolžan V,. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol, 2008; 64: 871-876.